About
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Current Value
$20.501 Year Return
Current Value
$20.501 Year Return
Key Details
Market Cap
$1.58B
P/E Ratio
-35.93
1Y Stock Return
20.49%
1Y Revenue Growth
56.60%
Dividend Yield
0.00%
Price to Book
3.6
Strategies that include KNSA
Double maintains 2 strategies that include KNSA - Kiniksa Pharmaceuticals International Plc
Growth at a Fair Price
High risk
$1,000
These stocks above $1B in Market Cap are modestly valued (PE below 15) but are in the top 20% of stocks for revenue growth over the past 5 years. We weight them by market cap.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
195
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Stock's related to KNSA
The stocks that are correlated to KNSA - Kiniksa Pharmaceuticals International Plc are KREF, EFSC, FATE, MBIN, NBTB
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 46.63% | $702.98M | +4.40% | 9.93% | |
| 44.58% | $1.81B | +24.71% | 2.32% | |
| 42.94% | $77.93M | -90.24% | 0.00% | |
| 42.15% | $1.54B | -19.35% | 1.16% | |
| 41.93% | $1.87B | +12.20% | 3.52% | |
| 37.56% | $6.90B | -3.21% | 0.00% | |
| 37.40% | $534.33M | +10.17% | 8.38% | |
 TCBKTriCo Bancshares | 37.38% | $1.22B | +8.00% | 3.57% |
| 37.30% | $924.65M | -54.58% | 0.00% | |
| 37.13% | $667.17M | +11.73% | 3.80% | |
| 37.12% | $1.78B | -14.39% | 5.11% | |
| 37.02% | $545.49M | +5.67% | 5.01% | |
| 36.99% | $6.46B | +5.01% | 4.08% | |
 PNRPentair plc | 36.73% | $13.45B | -1.52% | 1.20% |
| 36.72% | $1.64B | -43.30% | 0.00% | |
| 36.70% | $306.41M | +41.39% | 2.40% | |
| 36.61% | $533.57M | -3.59% | 5.13% | |
 SAPSAP SE | 36.34% | $308.38B | +38.38% | 0.94% |
| 35.98% | $1.35B | +9.29% | 2.21% | |
| 35.91% | $713.23M | -72.41% | 0.00% | |
ETF's related to KNSA
The ETFs that are correlated to KNSA - Kiniksa Pharmaceuticals International Plc are CPRJ, IWC, XBI, IWN, FYX
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 44.79% | $48.65M | 0.69% | |
| 41.39% | $809.63M | 0.6% | |
| 40.93% | $5.06B | 0.35% | |
| 37.93% | $11.04B | 0.24% | |
| 37.60% | $842.66M | 0.6% | |
| 37.60% | $63.84B | 0.19% | |
| 37.59% | $11.24B | 0.07% | |
| 37.47% | $715.67M | 0.38% | |
| 37.30% | $521.56M | 0.2% | |
| 37.07% | $48.48M | 0.5% | |
| 36.90% | $2.38B | 0.39% | |
| 36.84% | $1.41B | 0.47% | |
| 36.14% | $634.96M | 0.37% | |
| 35.70% | $10.93B | 0.24% | |
| 35.60% | $141.74M | 0.5% | |
| 35.47% | $1.44B | 0.39% | |
| 35.34% | $582.47M | 0.38% | |
| 35.17% | $5.92B | 0.18% | |
| 35.09% | $79.87B | 0.06% | |
| 35.07% | $16.19B | 0.04% | |
News
Yahoo
The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Yahoo
The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. Here are three no-brainer healthcare stocks to buy with $1,000 right now. AbbVie's product lineup is led by blockbuster drugs targeting autoimmune diseases, with Rinvoq and Skyrizi delivering especially strong sales growth.
Yahoo
We recently compiled a list of the 10 Best UK Growth Stocks to Buy Now. In this article, we are going to take a look at where Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) stands against the other UK growth stocks. The start of this year has marked interesting developments for the UK market. The main stock market […]
Yahoo
Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Yahoo
Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds